| 0.452 0.025 (5.85%) | 04-19 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.65  |
1-year : | 0.76 |
| Resists | First : | 0.56 |
Second : | 0.65 |
| Pivot price | 0.47  |
|||
| Supports | First : | 0.4 |
Second : | 0.3 |
| MAs | MA(5) : | 0.4 |
MA(20) : | 0.47 |
| MA(100) : | 0.86 |
MA(250) : | 1.06 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 45.2 |
D(3) : | 34.5 |
| RSI | RSI(14): 43.2 |
|||
| 52-week | High : | 3.27 | Low : | 0.25 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ RDHL ] has closed above bottom band by 40.4%. Bollinger Bands are 69.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 45 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.45 - 0.46 | 0.46 - 0.46 |
| Low: | 0.4 - 0.4 | 0.4 - 0.4 |
| Close: | 0.45 - 0.45 | 0.45 - 0.46 |
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and has completed Phase 2 studies for irritable bowel syndrome with diarrhea; and RHB-106, an encapsulated formulation for bowel preparation, which is preparing for Phase 2/3 study. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.
Thu, 18 Apr 2024
RedHill Biopharma (NASDAQ:RDHL) Now Covered by StockNews.com - Defense World
Thu, 04 Apr 2024
RedHill Biopharma Secures $1.25M in Direct Offering - TipRanks.com - TipRanks
Wed, 03 Apr 2024
RedHill Biopharma's Premium Direct Offering - TipRanks.com - TipRanks
Tue, 02 Apr 2024
RedHill Biopharma Announces $1.25 Million Registered Direct Offering at a Premium to Market Price - PR Newswire
Thu, 21 Mar 2024
RedHill Biopharma Share Capital Increase Approved - TipRanks.com - TipRanks
Thu, 25 Jan 2024
Premarket Mover: RedHill Biopharma Ltd (RDHL) Up 5.56% - InvestorsObserver
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 0 (M) |
| Shares Float | 32 (M) |
| Held by Insiders | 3.3e+009 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 376 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.088e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 366.2 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 60.7 % |
| Return on Equity (ttm) | -15.8 % |
| Qtrly Rev. Growth | 6.53e+006 % |
| Gross Profit (p.s.) | -27.64 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 4 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -36 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 6.51 |
| Dividend | 0 |
| Forward Dividend | 906880 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|